{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T05:44:16Z","timestamp":1786167856546,"version":"build-2736575974"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004286","name":"Santen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004286","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Jpn J Ophthalmol"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To evaluate the long-term safety and intraocular pressure (IOP)-lowering efficacy of sepetaprost, a novel dual FP\/EP3 receptor agonist, in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study design<\/jats:title>\n                    <jats:p>ANGEL-J2 (NCT05503901) was a phase 3, randomised, parallel-group, open-label study across 20\u00a0sites in Japan.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Adult patients with IOP \u226516 and &lt;22 mmHg were assigned to once-daily sepetaprost 0.002% (Group 1), whereas patients with IOP \u226522 and \u226434 mmHg were randomised 1:1 to once-daily sepetaprost 0.002% alone (Group 2) and with twice-daily timolol 0.5% (Group 3). Over 52 weeks of treatment, efficacy was assessed as the change in mean diurnal IOP from baseline; safety outcomes included the incidence of adverse drug reactions (ADRs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In total, 131 patients were assigned to Group 1 (n=49), Group 2 (n=42), or Group 3 (n=40). In each group, treatment was associated with rapid and sustained reductions in IOP versus baseline (\n                      <jats:italic>p<\/jats:italic>\n                      &lt;0.0001 at all time-points). Mean (\u00b1 standard error) change in diurnal IOP from baseline at week 52 was \u22124.40\u00b10.24, \u22126.38\u00b10.32, and \u22127.51\u00b10.29 mmHg in Groups 1, 2, and 3, respectively; similarly, mixed model for repeated measures analyses found that reductions in mean diurnal IOP over 52 weeks were greater in Group 3 versus Group 2. ADRs were reported in 80 patients overall (59.2\u201365.0% across groups), most commonly mild eyelash growth (22.4\u201342.5%) and mild conjunctival hyperaemia (28.6\u201330.6%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Sepetaprost, with or without timolol, demonstrated good tolerability and may represent an efficacious long-term treatment option for OAG or OHT.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10384-026-01351-2","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T02:56:54Z","timestamp":1781578614000},"page":"940-948","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Long-term safety and efficacy of sepetaprost, with or without timolol, in patients with open-angle glaucoma or ocular hypertension: results from the randomised, phase 3 ANGEL-J2 study"],"prefix":"10.1007","volume":"70","author":[{"given":"Masaru","family":"Inatani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Tone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiro","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5209-9131","authenticated-orcid":false,"given":"Raymund","family":"Angeles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,16]]},"reference":[{"key":"1351_CR1","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/S0002-9394(00)00538-9","volume":"130","author":"The AGIS Investigators","year":"2000","unstructured":"The AGIS Investigators. The advanced glaucoma intervention study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol. 2000;130:429\u201340.","journal-title":"Am J Ophthalmol"},{"key":"1351_CR2","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1001\/archopht.120.6.701","volume":"120","author":"MA Kass","year":"2002","unstructured":"Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, et al. The Ocular hypertension treatment study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:701\u201313.","journal-title":"Arch Ophthalmol"},{"key":"1351_CR3","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1001\/archopht.121.1.48","volume":"121","author":"MC Leske","year":"2003","unstructured":"Leske MC, Heijl A, Hussein M, Bengtsson B, Hyman L, Komaroff E. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol. 2003;121:48\u201356.","journal-title":"Arch Ophthalmol"},{"key":"1351_CR4","doi-asserted-by":"publisher","first-page":"e144","DOI":"10.1016\/S2214-109X(20)30489-7","volume":"9","author":"GBD 2019 blindness and vision impairment collaborators, vision loss expert group of the global burden of disease study","year":"2021","unstructured":"GBD 2019 blindness and vision impairment collaborators, vision loss expert group of the global burden of disease study. Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis for the Global Burden of Disease Study. Lancet Glob Health. 2021;9:e144\u201360.","journal-title":"Lancet Glob Health"},{"key":"1351_CR5","doi-asserted-by":"publisher","first-page":"P71","DOI":"10.1016\/j.ophtha.2020.10.022","volume":"128","author":"SJ Gedde","year":"2021","unstructured":"Gedde SJ, Vinod K, Wright MM, Muir KW, Lind JT, Chen PP, et al. Primary open-angle glaucoma Preferred Practice Pattern\u00ae. Ophthalmology. 2021;128:P71-150.","journal-title":"Ophthalmology"},{"key":"1351_CR6","first-page":"1","volume":"105","author":"European Glaucoma Society","year":"2021","unstructured":"European Glaucoma Society. European glaucoma society terminology and guidelines for glaucoma, 5th Edition. Br J Ophthalmol. 2021;105:1\u2013169.","journal-title":"Br J Ophthalmol"},{"key":"1351_CR7","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s10384-022-00970-9","volume":"67","author":"Y Kiuchi","year":"2023","unstructured":"Kiuchi Y, Inoue T, Shoji N, Nakamura M, Tanito M. The Japan glaucoma society guidelines for glaucoma 5th edition. Jpn J Ophthalmol. 2023;67:189\u2013254.","journal-title":"Jpn J Ophthalmol"},{"key":"1351_CR8","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.ogla.2020.09.002","volume":"4","author":"GF Schwartz","year":"2021","unstructured":"Schwartz GF, Patel A, Naik R, Lunacsek O, Ogbonnaya A, Campbell J. Characteristics and treatment patterns of newly diagnosed open-angle glaucoma patients in the United States: an administrative database analysis. Ophthalmol Glaucoma. 2021;4:117\u201325.","journal-title":"Ophthalmol Glaucoma"},{"key":"1351_CR9","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1080\/17469899.2019.1635456","volume":"14","author":"AL Robin","year":"2019","unstructured":"Robin AL, Muir KW. Medication adherence in patients with ocular hypertension or glaucoma. Expert Rev Ophthalmol. 2019;14:199\u2013210.","journal-title":"Expert Rev Ophthalmol"},{"key":"1351_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.1015338","volume":"13","author":"L Zhou","year":"2022","unstructured":"Zhou L, Zhan W, Wei X. Clinical pharmacology and pharmacogenetics of prostaglandin analogues in glaucoma. Front Pharmacol. 2022;13:1015338.","journal-title":"Front Pharmacol"},{"key":"1351_CR11","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.ajo.2020.06.003","volume":"220","author":"M Aihara","year":"2020","unstructured":"Aihara M, Lu F, Kawata H, Iwata A, Odani-Kawabata N, Shams NK. Omidenepag isopropyl versus latanoprost in primary open-angle glaucoma and ocular hypertension: the phase 3 AYAME study. Am J Ophthalmol. 2020;220:53\u201363.","journal-title":"Am J Ophthalmol"},{"key":"1351_CR12","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1007\/s10384-021-00868-y","volume":"65","author":"M Aihara","year":"2021","unstructured":"Aihara M, Lu F, Kawata H, Iwata A, Odani-Kawabata N. Twelve-month efficacy and safety of omidenepag isopropyl, a selective EP2 agonist, in open-angle glaucoma and ocular hypertension: the RENGE study. Jpn J Ophthalmol. 2021;65:810\u20139.","journal-title":"Jpn J Ophthalmol"},{"key":"1351_CR13","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1007\/s10384-024-01052-8","volume":"68","author":"K Inoue","year":"2024","unstructured":"Inoue K, Shiokawa M, Kunimatsu-Sanuki S, Kang J, Uraki T, Tomita G, et al. Three-year efficacy and safety of omidenepag isopropyl in patients with normal tension glaucoma. Jpn J Ophthalmol. 2024;68:206\u201310.","journal-title":"Jpn J Ophthalmol"},{"key":"1351_CR14","first-page":"1475","volume":"43","author":"U Schl\u00f6tzer-Schrehardt","year":"2002","unstructured":"Schl\u00f6tzer-Schrehardt U, Zenkel M, N\u00fcsing RM. Expression and localization of FP and EP prostanoid receptor subtypes in human ocular tissues. Invest Ophthalmol Vis Sci. 2002;43:1475\u201387.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1351_CR15","doi-asserted-by":"publisher","first-page":"3395","DOI":"10.1167\/iovs.06-0100","volume":"47","author":"T Ota","year":"2006","unstructured":"Ota T, Aihara M, Saeki T, Narumiya S, Araie M. The effects of prostaglandin analogues on prostanoid EP1, EP2, and EP3 receptor-deficient mice. Invest Ophthalmol Vis Sci. 2006;47:3395\u20139.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1351_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/jop.2008.0089","volume":"25","author":"BT Gabelt","year":"2009","unstructured":"Gabelt BT, Hennes EA, Bendel MA, Constant CE, Okka M, Kaufman PL. Prostaglandin subtype-selective and non-selective IOP-lowering comparison in monkeys. J Ocul Pharmacol Ther. 2009;25:1\u20138.","journal-title":"J Ocul Pharmacol Ther"},{"key":"1351_CR17","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.63.2.24","volume":"63","author":"R Yamagishi-Kimura","year":"2022","unstructured":"Yamagishi-Kimura R, Honjo M, Aihara M. The roles played by FP\/EP3 receptors during pressure-lowering in mouse eyes mediated by a dual FP\/EP3 receptor agonist. Invest Ophthalmol Vis Sci. 2022;63:24.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1351_CR18","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.1167\/iovs.14-16181","volume":"56","author":"S Yamane","year":"2015","unstructured":"Yamane S, Karakawa T, Nakayama S, Nagai K, Moriyuki K, Neki S, et al. IOP-lowering effect of ONO-9054, a novel dual agonist of prostanoid EP3 and FP receptors, in monkeys. Invest Ophthalmol Vis Sci. 2015;56:2547\u201352.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1351_CR19","unstructured":"Santen Pharmaceutical Co., Ltd. Santen obtains manufacturing and marketing approval in Japan for SETANEO\u00ae 0.002% ophthalmic solution, a bicyclic prostaglandin derivative that acts on FP and EP3 receptors, for treatment of glaucoma and ocular hypertension. https:\/\/www.santen.com\/en\/news\/2025\/2025_1\/20250825. Accessed 10 Sept 2025."},{"key":"1351_CR20","doi-asserted-by":"publisher","first-page":"7963","DOI":"10.1167\/iovs.15-18166","volume":"56","author":"F Suto","year":"2015","unstructured":"Suto F, Rowe-Rendleman CL, Ouchi T, Jamil A, Wood A, Ward CL. A novel dual agonist of EP3 and FP receptors for OAG and OHT: safety, pharmacokinetics, and pharmacodynamics of ONO-9054 in healthy volunteers. Invest Ophthalmol Vis Sci. 2015;56:7963\u201370.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1351_CR21","doi-asserted-by":"publisher","first-page":"e826","DOI":"10.1097\/IJG.0000000000000449","volume":"25","author":"A Harris","year":"2016","unstructured":"Harris A, Ward CL, Rowe-Rendleman CL, Ouchi T, Wood A, Fujii A, et al. Ocular hypotensive effect of ONO-9054, an EP3\/FP receptor agonist: results of a randomized, placebo-controlled, dose escalation study. J Glaucoma. 2016;25:e826\u201333.","journal-title":"J Glaucoma"},{"key":"1351_CR22","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1136\/bjophthalmol-2015-307000","volume":"100","author":"MS Berlin","year":"2016","unstructured":"Berlin MS, Rowe-Rendleman C, Ahmed I, Ross DT, Fujii A, Ouchi T, et al. EP3\/FP dual receptor agonist ONO-9054 administered morning or evening to patients with open-angle glaucoma or ocular hypertension: results of a randomised crossover study. Br J Ophthalmol. 2016;100:843\u20137.","journal-title":"Br J Ophthalmol"},{"key":"1351_CR23","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1136\/bjophthalmol-2016-309023","volume":"101","author":"E Miller Ellis","year":"2017","unstructured":"Miller Ellis E, Berlin MS, Ward CL, Sharpe JA, Jamil A, Harris A. Ocular hypotensive effect of the novel EP3\/FP agonist ONO-9054 versus Xalatan: results of a 28-day, double-masked, randomised study. Br J Ophthalmol. 2017;101:796\u2013800.","journal-title":"Br J Ophthalmol"},{"key":"1351_CR24","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1089\/jop.2021.0077","volume":"38","author":"DL Wirta","year":"2022","unstructured":"Wirta DL, Kuwayama Y, Lu F, Shao H, Odani-Kawabata N. Phase 2b, randomized, 3-month, dose-finding study of sepetaprost in patients with primary open-angle glaucoma or ocular hypertension: the ANGEL study. J Ocul Pharmacol Ther. 2022;38:240\u201351.","journal-title":"J Ocul Pharmacol Ther"},{"key":"1351_CR25","doi-asserted-by":"publisher","first-page":"3810","DOI":"10.1007\/s12325-025-03227-2","volume":"42","author":"AG Konstas","year":"2025","unstructured":"Konstas AG, Garh\u00f6fer G, L\u00fcbke J, Voykov B, Ropo A. A study of 24-h efficacy and safety of sepetaprost vs. latanoprost in patients with primary open-angle glaucoma or ocular hypertension. Adv Ther. 2025;42:3810\u201325.","journal-title":"Adv Ther"},{"key":"1351_CR26","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.ogla.2025.02.004","volume":"8","author":"DL Wirta","year":"2025","unstructured":"Wirta DL, El-Harazi SM, Tepedino ME, Bacharach J. Sepetaprost 0.002% noninferiority vs. timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension: ANGEL-2. Ophthalmol Glaucoma. 2025;8:384\u201392.","journal-title":"Ophthalmol Glaucoma"},{"key":"1351_CR27","doi-asserted-by":"publisher","unstructured":"Inatani M, Kanamori A, Angeles R, Ikeda T, Inai M. Efficacy and safety of sepetaprost in patients with primary open-angle glaucoma or ocular hypertension: results from the randomised, phase 3 ANGEL-J1 study. Jpn J Ophthalmol. https:\/\/doi.org\/10.1007\/s10384-026-01350-3","DOI":"10.1007\/s10384-026-01350-3"},{"key":"1351_CR28","unstructured":"International Council for Harmonisation. ICH E1 Guideline: the extent of population exposure to assess clinical safety for drugs intended for long-term treatment of non-life-threatening conditions. https:\/\/www.ich.org\/page\/efficacy-guidelines. Accessed 2 Feb 2026."},{"key":"1351_CR29","doi-asserted-by":"publisher","first-page":"539","DOI":"10.2147\/JEP.S281187","volume":"12","author":"V Jayanetti","year":"2020","unstructured":"Jayanetti V, Sandhu S, Lusthaus JA. The latest drugs in development that reduce intraocular pressure in ocular hypertension and glaucoma. J Exp Pharmacol. 2020;12:539\u201348.","journal-title":"J Exp Pharmacol"},{"key":"1351_CR30","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1080\/14740338.2024.2436062","volume":"24","author":"G Holl\u00f3","year":"2025","unstructured":"Holl\u00f3 G. Ocular hyperemia associated with topical glaucoma medication: understanding and differentiating clinical appearance and underlying mechanisms. Expert Opin Drug Saf. 2025;24:145\u201356.","journal-title":"Expert Opin Drug Saf"},{"key":"1351_CR31","unstructured":"Japanese Pharmaceuticals and Medical Devices Agency. Materials regarding Tapros ophthalmic solution 0.0015% (generic name: tafluprost). https:\/\/www.pmda.go.jp\/drugs\/2008\/P200800044\/index.html. Accessed 3 June 2025.(in Japanese)"},{"key":"1351_CR32","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1001\/archopht.120.10.1286","volume":"120","author":"EJ Higginbotham","year":"2002","unstructured":"Higginbotham EJ, Schuman JS, Goldberg I, Gross RL, VanDenburgh AM, Chen K. One-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension. Arch Ophthalmol. 2002;120:1286\u201393.","journal-title":"Arch Ophthalmol"},{"key":"1351_CR33","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/S0002-9394(01)01177-1","volume":"132","author":"PA Netland","year":"2001","unstructured":"Netland PA, Landry T, Sullivan EK, Andrew R, Silver L, Weiner A, et al. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol. 2001;132:472\u201384.","journal-title":"Am J Ophthalmol"},{"key":"1351_CR34","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1001\/archopht.123.2.186","volume":"123","author":"ES Arcieri","year":"2005","unstructured":"Arcieri ES, Santana A, Rocha FN, Guapo GL, Costa VP. Blood-aqueous barrier changes after the use of prostaglandin analogues in patients with pseudophakia and aphakia: a 6-month randomized trial. Arch Ophthalmol. 2005;123:186\u201392.","journal-title":"Arch Ophthalmol"},{"key":"1351_CR35","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1080\/08820538.2021.2003824","volume":"37","author":"R Sakata","year":"2022","unstructured":"Sakata R, Chang PY, Sung KR, Kim TW, Wang TH, Perera SA, et al. Prostaglandin-associated periorbitopathy syndrome (PAPS): addressing an unmet clinical need. Semin Ophthalmol. 2022;37:447\u201354.","journal-title":"Semin Ophthalmol."},{"key":"1351_CR36","first-page":"1641","volume":"111","author":"A Iwase","year":"2004","unstructured":"Iwase A, Suzuki Y, Araie M, Yamamoto T, Abe H, Shirato S, et al. The prevalence of primary open-angle glaucoma in Japanese: the Tajimi Study. Ophthalmology. 2004;111:1641\u20138.","journal-title":"Ophthalmology"}],"container-title":["Japanese Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-026-01351-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10384-026-01351-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-026-01351-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T05:23:10Z","timestamp":1786166590000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10384-026-01351-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,16]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1351"],"URL":"https:\/\/doi.org\/10.1007\/s10384-026-01351-2","relation":{},"ISSN":["0021-5155","1613-2246"],"issn-type":[{"value":"0021-5155","type":"print"},{"value":"1613-2246","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,16]]},"assertion":[{"value":"10 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M. Inatani, Scholarship donation (Santen, Kowa, Senju, Alcon, Chugai, HOYA, Johnson & Johnson, NIDEK, Otsuka); Consulting fees (Santen, Senju), Honoraria for presentations (Santen, Kowa, Alcon, Chugai, HOYA, Johnson & Johnson, NIDEK, Otsuka, Glaukos, Viatris, Novartis, Bayer, JFC, Sandoz, Rohto, Inami), Expert testimony (Glaukos, the Japanese Pharmaceuticals and Medical Devices Agency), Advisory fee (Santen), Trustee roles for the Japan Glaucoma Society and Japanese Ophthalmological Society; Y. Tone, Patents (Santen), Employee (Santen); T. Ikeda, Employee (Santen); R. Angeles, Employee (Santen).","order":1,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}